Production (Stage)
IGC Pharma, Inc.
IGC
$0.3808
-$0.0342-8.24%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.86% | 25.98% | 41.58% | -50.99% | 77.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.86% | 25.98% | 41.58% | -50.99% | 77.71% |
| Cost of Revenue | 41.94% | 115.49% | 82.91% | -63.67% | 20.39% |
| Gross Profit | -9.94% | -21.80% | 13.79% | -36.08% | 171.43% |
| SG&A Expenses | -72.27% | -49.28% | -25.48% | 1.04% | -39.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.19% | -33.32% | -21.93% | -1.20% | -25.59% |
| Operating Income | 49.86% | 37.36% | 29.35% | -11.85% | 29.72% |
| Income Before Tax | 58.51% | 67.28% | 29.95% | -14.60% | 28.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 58.51% | 67.28% | 29.95% | -14.60% | 28.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 58.51% | 67.28% | 29.95% | -14.60% | 28.41% |
| EBIT | 49.86% | 37.36% | 29.35% | -11.85% | 29.72% |
| EBITDA | 52.47% | 39.36% | 30.78% | -12.42% | 31.13% |
| EPS Basic | 66.59% | 73.09% | 49.89% | 16.37% | 40.84% |
| Normalized Basic EPS | 65.16% | 49.48% | 50.00% | 16.53% | 40.58% |
| EPS Diluted | 66.59% | 73.09% | 49.89% | 16.37% | 40.84% |
| Normalized Diluted EPS | 65.16% | 49.48% | 50.00% | 16.53% | 40.58% |
| Average Basic Shares Outstanding | 23.88% | 21.82% | 39.97% | 37.18% | 21.06% |
| Average Diluted Shares Outstanding | 23.88% | 21.82% | 39.97% | 37.18% | 21.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |